|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| The Evolution of DTC marketing across key pharmaceutical markets |
|
|
|
|
€ 955,00 |
Editeur
: |
Business Insight |
Langue
: |
Anglais |
Date de publication : |
Mars 2000 |
Taille du document : |
152 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 203 pages | Mai 2000 | Anglais
|
|
|
| Main
focus: |
hospitals,hospital,emergency,healthcare,...
|
| Research
focus: |
market size and estimates,demand analysis, |
| Geographic
focus: |
usa,france,united kingdom,germany,luxembourg,... |
| |
|
|
|
|
| 148 pages | Juin 2005 | Anglais
|
|
|
| Main
focus: |
healthcare,health care,dentists,dentist,...
|
| Research
focus: |
industry structure,market outlook, |
| Geographic
focus: |
usa,france,india |
| |
|
|
|
|
| 84 pages | Juillet 2005 | Anglais
|
|
|
| Main
focus: |
healthcare,health care,dentists,life sciences,...
|
| Research
focus: |
demand analysis,competition analysis, |
| Geographic
focus: |
usa,mexico,india,united kingdom |
| |
|
|
|
|
| 79 pages | Août 2006 | Anglais
|
|
|
| Main
focus: |
healthcare,health care,dentist,pharmaceutical,...
|
| Research
focus: |
market size and estimates,competition analysis, |
| Geographic
focus: |
usa,germany,china,japan,united kingdom,france,... |
| |
|
|
|
|
| 78 pages | Janvier 2005 | Anglais
|
|
|
| Main
focus: |
healthcare,health care,healthcare informatics,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,canada,united kingdom,australia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Japanese Pharmaceutical Market Outlook 2001 142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies. Now, however, extensive cultur |
1 200,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008 165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
Healthcare In Scotland 52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets 214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals. Mar |
795,00 €
|
| |
| |
Maximising the Drug Lifecycle 102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
The Pharmaceutical Industry Paradox: A strategic analysis of the countertrends of consolidation and fragmentation 128 pages | Mai 2002 |
The pharmaceutical industry currently represents a huge paradox. Whilst the pursuit of critical mass has driven consolidation and brought about the creation of mega-companies such as Pharmacia, Gla |
953,48 €
|
| |
| |
Pharmaceutical Mergers & Aquisitions: the third wave 160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
|
795,00 €
|
| |
| |
OTC Digestive Remedies in Germany 15 pages | Juillet 2002 |
The German market for OTC digestive remedies totaled Euro 446.9 million (US$421.9 million) in 2001, an increase of nearly 1% on the previous year and they remain important with a 11% share of all self |
198,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium 240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The Evolution of DTC marketing across key pharmaceutical markets |
|
|
 
 
Pharmaceutical companies mainly market their products through contact between  
  their sales force and heathcare providers.
 
  However, due to the nature of its products, the pharmaceutical industry has  
  been subject to heavier marketing and advertising restrictions than most other  
  industries and have remained focused on the purchasers and providers of healthcare,  
  rather than the consumers.
 
  For many years, the pharmaceutical industry believed that it was being denied  
  access to the most influential sector of the healthcare industry: the patient  
  sector.  
 
However, in August 1997, the FDA relaxed the regulations governing the use  
  and nature of DTC promotion within ethical pharmaceutical marketing strategies  
  in the US. Today, US patients are targeted with product specific information  
  and prompted take a more active role in the prescribing process.
 
  Encouraged by the example of the FDA, supporters of DTC advertising are exerting  
  increasing pressure on European authorities to relax their ban on DTC marketing  
  in Europe.  
 
The evolution of DTC marketing across key pharmaceutical markets gauges  
  the global development of DTC marketing by analyzing the reality of DTC marketing  
  in the US and assessing the likelihood of cultural and formal acceptance of  
  DTC marketing in other major markets.  
 
One stop shop :
 
  The national and international implications for healthcare professionals, providers  
  and patients are analyzed using detailed data, case studies and insightful opinion  
  to give a clear picture of the current and future role of DTC marketing.  
 
Global issues :
 
  The suitability of DTC marketing to different therapy areas and healthcare systems  
  is discussed along with the commercial implications to companies in Europe and  
  the US.  
 
The potential for DTC in Europe :
 
  The likelihood of a change in the European DTC marketing regulations is considered,  
  alongside the implications for providers and receivers of healthcare in Europe  
 
 
 
Strategic DTC decisions :
 
  The benefits and disadvantages of electronic, television and print DTC marketing  
  are identified, and the optimal strategies for the use of DTC marketing through  
  the product life cycle are pinpointed
|
|
Chapter 1: What is DTC marketing and where is it permitted?
Chapter 2: DTC marketing in the US: segmentation of investment
Chapter 3: DTC marketing in the US: strategic decisions
Chapter 4: New DTC Markets?
Chapter 5: Appendix
|
|
|
PPLSEN
|
|
|
|
|